Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.
Medivir has named Linda Basse, M.D., Ph.D., as chief medical officer. The appointment puts a leader who played a starring role in the development of Darzalex in charge of ushering Medivir’s clinical pipeline through a critical period.